AI for Pharma: Regulated Content at Scale

Quick answer — Pharmaceutical content splits in two. Regulatory submissions need traceability and an audit trail more than speed; patient and commercial content needs reach and clarity. AI serves both, and confusing them is the usual failure.

Two content estates, one company

On one side: dossiers, labelling, safety reporting, protocols. Highly structured, heavily reviewed, and judged on whether every change can be traced to a person and a date. On the other: patient information, adherence material, HCP education, market access decks. Judged on whether anyone understands them.

They are frequently owned by the same localization budget and almost never by the same standard. A platform that serves one badly serves the company badly, because the regulatory side will simply refuse to use it.

Traceability is the regulatory requirement

Not speed. An inspector asks who approved this rendering, when, and against what source version. A tool that cannot answer that is unusable in the regulated estate however good its output is, which is the whole audit-trail question.

quality control with reviewer sign-off produces that record as a by-product of the work rather than as a separate documentation exercise.

Terminology is not negotiable

MedDRA terms, INNs, dosage forms and route-of-administration language are controlled vocabularies. A synonym that reads better is a deviation.

Lock them in translation memory and let the glossary refuse improvement.

Patient material has the opposite problem

Readability, not precision. A patient information leaflet that is technically perfect and incomprehensible has failed, and several regulators now test comprehension directly.

Where to start

The audit trail, before any volume. Then patient material, where the gains are largest and the risk lowest.

How pharma brands localize for global markets covers the programme; pharma translation covers the formats.

The document classes, one by one

Pharma content is not one workflow. It is a set of document classes with different readers and different consequences, and each has its own article: SmPC and the patient leaflet for product information, IFU for devices, and informed consent where comprehension is the legal test rather than accuracy.

On the submission side there is the CTD dossier and clinical study reports, and after approval, pharmacovigilance on a reporting clock.

Then the commercial and operational surfaces: packaging artwork, detail aids for field teams, and training video where the output is an audit record.

FAQ

How does pharma content divide for translation? Into a regulated estate — dossiers, labelling, safety reporting, protocols — judged on traceability, and a patient and commercial estate judged on whether anyone understands it. The standards are opposite.

What does a regulator actually ask about a translation? Who approved this rendering, when, and against which source version. A tool that cannot answer those three questions is unusable in the regulated estate regardless of output quality.

Can pharma terminology be improved by a translator? No. MedDRA terms, international non-proprietary names, dosage forms and route-of-administration language are controlled vocabularies, so a synonym that reads better is a deviation.

What is the failure mode for patient information? Technical perfection nobody understands. Readability is the standard on that side of the estate, and several regulators now test patient comprehension directly rather than accepting the text as filed.